Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct 22:9:584.
doi: 10.3332/ecancer.2015.584. eCollection 2015.

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer

Nicoletta Tomasi Cont  1 , Annamaria Ferrero  1 , Fedro Alessandro Peccatori  2 , Marta D'Alonzo  1 , Giovanni Codacci-Pisanelli  3 , Nicoletta Colombo  4 , Nicoletta Biglia  1
Affiliations
Review

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer

Nicoletta Tomasi Cont et al. Ecancermedicalscience. .

Abstract

Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge. For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains uncertain. Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects. Furthermore, personal factors, such as the patient's performance status, should be taken into account in the management of ovarian cancer, with the aim of safeguarding the patients' quality of life.

Keywords: biological markers; ovarian neoplasm; personalised medicine.

PubMed Disclaimer

References

    1. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413–437. doi: 10.1007/978-1-60327-492-0_20. - DOI - PubMed
    1. Prat J. New insight into ovarian cancer pathology. Ann Oncol. 2012;23(10):111–117. doi: 10.1093/annonc/mds300. - DOI - PubMed
    1. The cancer genome atlas research network. Integrated genomic analysis of ovarian carcinoma. Nature. 2011;474(7353):609–615. doi: 10.1038/nature10166. - DOI - PMC - PubMed
    1. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420–432. doi: 10.1097/PAT.0b013e328348a6e7. - DOI - PubMed
    1. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014;2014 doi: 10.1155/2014/934261. - DOI - PMC - PubMed